Selected article for: "Cox proportional hazard model and hazard model"

Author: Morieri, Mario Luca; Bonora, Benedetta Maria; Longato, Enrico; Di Camilo, Barbara; Sparacino, Giovanni; Tramontan, Lara; Avogaro, Angelo; Fadini, Gian Paolo
Title: Exposure to DPP-4 inhibitors and risk of pneumonia among people with type 2 diabetes. Retrospective cohort study and meta-analysis.
  • Cord-id: twwmsqfw
  • Document date: 2020_7_20
  • ID: twwmsqfw
    Snippet: AIMS Concerns have been raised that dipeptidyl-peptidase 4 inhibitors (DPP-4i) may increase the risk of pneumonia. We analysed observational data and clinical trials to explore whether use of DPP-4i modifies the risk of pneumonia. METHODS We identified patients with diabetes in the Veneto Region administrative database and performed a propensity score matching (PSM) between new users of DPP-4 inhibitors and new users of other oral glucose lowering medications (OGLM). We compared the rate of hosp
    Document: AIMS Concerns have been raised that dipeptidyl-peptidase 4 inhibitors (DPP-4i) may increase the risk of pneumonia. We analysed observational data and clinical trials to explore whether use of DPP-4i modifies the risk of pneumonia. METHODS We identified patients with diabetes in the Veneto Region administrative database and performed a propensity score matching (PSM) between new users of DPP-4 inhibitors and new users of other oral glucose lowering medications (OGLM). We compared the rate of hospitalization for pneumonia between matched cohorts using the Cox proportional hazard model. The same analysis was repeated using the database of a local diabetes outpatient clinic. We retrieved similar observational studies from the literature to perform a meta-analysis. Results from trials reporting pneumonia rates among patients randomized to DPP-4 inhibitors versus placebo/active comparator were also meta-analysed. RESULTS In the Regional database, after matching 6495 patients/group, new users of DPP-4 inhibitors had a lower rate of hospitalization for pneumonia than new users of other OGLM (HR 0.76; 95% C.I. 0.61-0.95). In the outpatient database, after matching 867 patients/group, new users of DPP-4 inhibitors showed a non-significantly lower rate of hospitalization for pneumonia (HR 0.65; 95% C.I. 0.41-1.04). The meta-analysis of observational studies yielded an overall non-significant lower risk of hospitalization for pneumonia among DPP-4i users (RR 0.81; 95% C.I. 0.65-1.01). The meta-analysis of randomized controlled trials showed no overall effect of DPP-4i on pneumonia risk (RR 1.06; 95% C.I. 0.93-1.20). CONCLUSION Use of DPP-4i can be considered safe with regards to the risk of pneumonia. This article is protected by copyright. All rights reserved.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1